GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
- Conditions
- Hemophilia A
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT03154437
- Locations
- 🇺🇸
Tulane Medical Center; Investigational/Research Pharmacy, New Orleans, Louisiana, United States
🇺🇸Children's Mercy Hosp Clinics, Kansas City, Missouri, United States
🇺🇸University of Texas Medical School, Houston, Texas, United States
A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT03137069
- Locations
- 🇨🇦
Gordon Sussman Clinical Research, Toronto, Ontario, Canada
🇺🇸New Horizon Research Center, Miami, Florida, United States
🇩🇪Universitätsmedizin Johannes Gutenberg Universität, Mainz, Germany
A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease
- Conditions
- Diabetes Mellitus, Type 2Non-Alcoholic Fatty Liver Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 154
- Registration Number
- NCT03060538
- Locations
- 🇺🇸
MD Clinical, Hallandale Beach, Florida, United States
🇺🇸MidWest Clinical Research, Overland Park, Kansas, United States
🇺🇸Premier Research Associate, Inc, Miami, Florida, United States
A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
- First Posted Date
- 2017-01-24
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03029832
- Locations
- 🇺🇸
Arizona Oncology - HOPE Wilmot, Tucson, Arizona, United States
🇺🇸Nebraska Methodist Hospital; Cancer Center, Omaha, Nebraska, United States
🇺🇸University of Colorado, Denver, Colorado, United States
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
- Conditions
- Breast CancerSolid Tumor
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT03006172
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇬🇧Royal Marsden Hospital - Surrey, Surrey, Sutton, United Kingdom
🇬🇧Royal Marsden Hospital - London, London, United Kingdom
A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)
- Conditions
- Healthy Volunteers
- Interventions
- Device: Auto-Injector (AI)Device: Prefilled Syringe With Needle Safety Device (PFS-NSD)
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT02996019
- Locations
- 🇺🇸
Covance Research Unit - Daytona, Daytona Beach, Florida, United States
🇺🇸Covance Clinical Research Unit Inc.; Covance Gfi Research, Evansville, Indiana, United States
🇺🇸Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States
A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 496
- Registration Number
- NCT02983227
- Locations
- 🇺🇦
CNI Consultative and Diagnostic Center of Desnianskyi District of Kyiv, Kyiv, Ukraine
🇵🇱Centrum Medyczne Pratia Katowice I, Katowice, Poland
🇵🇱CCBR - Lodz - PL, Lodz, Poland
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT02927301
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸UCLA Cancer Center, Santa Monica, California, United States
🇺🇸University Of Colorado, Aurora, Colorado, United States
A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 260
- Registration Number
- NCT02908100
- Locations
- 🇺🇸
Institute of Arthritis Research, Idaho Falls, Idaho, United States
🇺🇸Valerius Medical Group & Research Ctr of Greater Long Beach, Los Alamitos, California, United States
🇺🇸RASF-Clinical Research Center, Boca Raton, Florida, United States
A Study to Assess the Relative Bioavailability And Food Effect of a Tablet Formulation of GDC-0276 in Healthy Participants
- Conditions
- Healthy Volunteer
- Interventions
- Drug: GDC-0276 capsuleDrug: GDC-0276 tablets
- First Posted Date
- 2016-08-04
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT02856152
- Locations
- 🇬🇧
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom